Pregnancy and substance abuse

Current Opinion in Psychiatry

Volumn 14, Issue 3, 2001, Pages 187-193

  Jones, Hendrée E ^a,b   Johnson, Rolley E ^a  

^a Behav Pharmacol Res Unit   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CAFFEINE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; HYPNOTIC SEDATIVE AGENT; ILLICIT DRUG; NICOTINE; OPIATE; PSYCHEDELIC AGENT;

ALCOHOLISM; DRUG MISUSE; FETUS DEVELOPMENT; HUMAN; PREGNANCY; PRENATAL EXPOSURE; REVIEW; SCREENING; SUBSTANCE ABUSE;

EID: 0035008060     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200105000-00005     Document Type: Review

References (89)

1. 1 US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Rockville MD: DHHS Public Health Service, CDC Office on Smoking and Health, DHHS No. (CDC) 90-8416; 1990.
2. 2 Stratton K, Howe C, Battaglia F (editors). Fetal alcohol syndrome: diagnosis, epidemiology, prevention and treatment. Washington DC: National Academy Press; 1996.
3. 3 National Institute on Drug Abuse. National Pregnancy and Health Survey: Drug use among women delivering livebirths, 1992. Washington, DC: US Department of Health and Human Services, Publication No. 96-3819; 1996.
4. 4 Floyd RL, Decoufle P, Hungerford DW. Alcohol use prior to pregnancy recognition. Am J Prevent Med 1999; 17:101-107.
5. 5 Morse BA, Hutchins E. Reducing complications from alcohol use during pregnancy through screening. J Am Med Womens Assoc 2000; 55:225-227.
6. 6 Lemoine P, Harousseau H, Borteryu JP, Menuet JC. Les enfants de parents alcooliques: anomalies observées à propos de 127 cas. Ouest Medical 1968; 21:476-482.
7. 7 Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973; ii:999-1001.
8. 8 Kaskutas LA. Understanding drinking during pregnancy among urban American Indians and African Americans: health messages, risk beliefs, and how we measure consumption. Alcohol Clin Exp Res 2000; 24:1241-1250.
9. 9 Armstrong EM, Abel EL. Fetal alcohol syndrome: the origins of a moral panic. Alcohol Alcoholism 2000; 35:276-282. This study provides an interesting commentary on the public concern over FAS, and discusses the implications and scientific response to this concern.
10. 10 Astley SJ, Clarren SK. Diagnosing the full spectrum of fetal alcohol-exposed individuals: introducing the 4-digit diagnostic code. Alcohol 2000; 35:400-410. This study tested a new tool for diagnosing prenatal alcohol exposure and outcomes using a large sample size.
11. 11 Coles CD, Kable JA, Carolyn DB, Falek A. Early identification of risk effects of prenatal alcohol exposure. J Stud Alcohol 2000; 61:607-616.
12. 12 Hug TE, Fitzgerald KM, Cibis GW. Clinical and electroretinographic findings in fetal alcohol syndrome. J AAPOS 2000; 4:200-204.
13. 13 Mattson SN, Riley EP. Implicit and explicit memory functioning in children with heavy prenatal alcohol exposure. J Int Neuropsychol Soc 1999; 5:462-471.
14. 14 Autti-Ramo I. Twelve-year follow-up of children exposed to alcohol in utero. Dev Med Child Neurol 2000; 42:406-411.
15. 15 Chassin L, Pitts SC, DeLucia C, Todd M. A longitudinal study of children of alcoholics: predicting young adult substance use disorders, anxiety and depression. J Abnorm Psychol 2000; 108:106-119.
16. 16 O'Connor MJ, Kasari C. Prenatal alcohol exposure and depressive features in children. Alcohol Clin Exp Res 2000; 24:1084-1092.
17. 17 Roebuck TM, Mattson SN, Riley EP. Behavioral and psychological profiles of alcohol-exposed children. Alcohol Clin Exp Res 1999; 23:1070-1076.
18. 18 Shah BG, O'Connor MJ, Cronin P, et al. Psychopathology in children with varying levels of prenatal alcohol exposure. Poster presentation at the annual Research Society on Alcoholism, 26 June-1 July 1999, Santa Barbara, CA, USA.
19. 19 Ikonomidou C, Bittigau P, Ishimaru MJ, et al. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000; 287:1056-1059. An important article advancing the mechanistic actions of prenatal alcohol exposure causing damage to the developing brain.
20. 20 Abel EL. What really causes FAS. Teratology 1999; 59:4-6.
21. 21 Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000; 149:327-344.
22. 22 Kleinman JC, Kopstein A. Smoking during pregnancy 1967-1980. Am J Public Health 1987; 77:823-827.
23. 23 Fergusson DM. Prenatal smoking and antisocial behavior. Arch Gen Psychiatry 1999; 56:223-224.
24. 24 Brennan PA, Grekin ER, Mednick SA. Maternal smoking during pregnancy and adult male criminal outcomes. Arch Gen Psychiatry 1999; 56:215-219.
25. 25 Benowitz NL. Nicotine replacement therapy during pregnancy. JAMA 1991; 266:3174-3177.
26. 26 Johns JM, Lewis MT, Becker RF, Means LW. Behavioral effects of prenatal exposure to nicotine in guinea pigs. Neurobehav Toxicol Teratol 1982; 4:365-369.
27. 27 Oncken CA, Hatsukami DK, Lupo VR, et al. Effects of short-term use of nicotine gum in pregnancy smokers. Clin Pharmacol Ther 1996; 59:654-661.
28. 28 Wright LN, Thorp JM, Kuller JA, et al. Transdermal nicotine replacement in pregnancy: maternal pharmacokinetics and fetal effects. Am J Obstet Gynecol 1997; 176:1090-1094.
29. 29 Oncken CA, Hardardottir H, Hatsukami DK, et al. Effects of transdermal nicotine or smoking on nicotine concentrations and maternal-fetal hemodynamics. Obstet Gynecol 1997; 90:569-574.
30. 30 Ogburn PL, Hurt RD, Croghan RD, et al. Nicotine patch use in pregnant smokers: nicotine and cotinine levels and fetal effects. Am J Obstet Gynecol 1999; 181:763-743.
31. 31 Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: a randomized controlled study. Obstet Gynecol 2000; 96:967-971.
32. 32 Windsor R, Oncken C, Henningfield J, et al. Behavioral and pharmacological treatment methods for pregnant smokers: issues for clinical practice. J Am Med Womens Assoc 2000; 55:304-310.
33. 33 Eskenazi B. Caffeine use during pregnancy: grounds for concern? JAMA 1993; 270:2973-2974.
34. 34 Leviton A. Caffeine consumption and the risk of reproductive hazards. J Reprod Med 1988; 33:175-178.
35. 35 Cnattingius S, Signorello LB, Anneren G, et al. Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med 2000; 343:1839-1845. An important study documenting the risk of low caffeine consumption on first-trimester spontaneous abortion of fetuses with normal karyotypes.
36. 36 Torfs CP, Christianson RE. Effect of maternal smoking and coffee consumption on the risk of having a recognized Dawn's syndrome pregnancy. Am J Epidemiol 2000; 152:1185-1191.
37. 37 Plessinger MA, Woods JR. Cocaine in pregnancy recent data on maternal and fetal risks. Obstet Gynecol Clin North Am 1998; 25:99-113.
38. 38 Kuhn L, Kline J, Ng S, et al. Cocaine use during pregnancy and intrauterine growth retardation: new insights based on maternal hair tests. Am J Epidemiol 2000; 152:112-119.
39. 39 Bateman DA, Chiriboga CA. Dose-response effect of cocaine on newborn head circumference. Pediatrics 2000; 106:33-39. A well-controlled study that used both subjective and objective data documenting prenatal cocaine exposure. Data support asymmetric intrauterine head growth restriction.
40. 40 Kaltenbach K. The effects of maternal cocaine abuse on mothers and newborns. Curr Psychiatry Rep 2000; 2:514-518. An excellent review of recent research put into a historic prospective. It provides an overview of current knowledge related to perinatal outcomes, neurobehavioral effects and the effects of treatment on the mother and newborn.
41. 41 Woods JR. Maternal and transplacental effects of cocaine. Ann NY Acad Sci 1998; 846:1-11.
42. 42 Zachor DA, Moore JF, Jin J, et al. C-fos mediates cocaine ìnhibition of NGF-induced PC12 cell differentiation. Mol Genet Metab 1998; 64:62-69.
43. 43 Kosofsky BE, Wilkins AS. A mouse model of transplacental cocaine exposure: clinical implications for exposed infants and children. Ann NY Acad Sci 1998; 846:248-261.
44. 44 Cabrera-Vera TM, Garcia F, Pinto W, Battaglia G. Neurochemical changes in brain serotonin neurons in immature and adult offspring prenatally exposed to cocaine. Brain Res 2000; 870:1-9.
45. 45 Lipton JW, Ling Z, Vu TO, et al. Prenatal cocaine exposure reduces glial cell line-derived neurotrophic factor (GDNF) in the striatum and the carotid body of the rat: implications for DA neurodevelopment. Dev Brain Res 1999; 118:231-235.
46. 46 Shearman LP, Meyer JS. Cocaine up-regulates norepinephrine transporter binding in the rat placenta. Eur J Pharmacol 1999; 386:1-6.
47. 47 McElhatton PR, Bateman DN, Evans C, et al. Congenital anomalies after prenatal ecstasy exposure. Lancet 1999; 354:1441-1442.
48. 48 Marwick C. NIDA seeking data on effect of fetal exposure to methamphetamine. JAMA 2000; 283:2225-2226.
49. 49 Substance Abuse and Mental Health Services Administration Office of Applied Studies. Preliminary estimates from the Drug Abuse Warning Network. Washington, DC: US Department of Health and Human Services, Public Health Service; 1997.
50. 50 American Academy of Pediatrics. Committee on Drugs Policy Statement: Neonatal Drug Withdrawal (RE9746). Pediatrics 1998; 101:1079-1088.
51. 51 Marion IJ. Pregnant substance abusìng women. Treatment Improvement Protocol (TIP) Series. US Department of Health and Human Services, Public Health Service, Substance Abuse and Mental Health Service Administration, Center for Substance Abuse Treatment. Washington, DC: DHHS Publication No. (SMA) 95-3056; 1993.
52. 52 Grella CE, Joshi V, Hser YI. Program variation in treatment outcomes among women in residential drug treatment. Eval Rev 2000; 24:364-383.
53. 53 Fischer G. Treatment of opioid dependence in pregnant women. Addiction 2000; 95:1141-1144.
54. 54 Kandall SR, Doberczak TM, Jantunen M, et al. The methadone-maintained pregnancy. Clin Perinatol 1999; 26:173-183.
55. 55 Kyei-Aboagye K, Vragovic O, Chong D. Birth outcome in incarcerated, high-risk pregnant women. J Reprod Med 2000; 45:190-194.
56. 56 Anderson IB, Kearney TE. Use of methadone. West J Med 2000; 172:43-46.
57. 57 Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 1991; 23:191-201.
58. 58 Fischer G, Bitschnau M, Peternell A, et al. Pregnancy and substance abuse. Arch Women's Mental Health 1999; 2:57-65.
59. 59 Fischer G, Jagsch R, Eder H, et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999; 94:231-239.
60. 60 Jarvis ME, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis 2000; 18:51-61.
61. 61 Substance Abuse and Mental Health Services Administration. 1995 Preliminary estimates from the Drug Abuse Warning Network. Washington DC, US Department of Health and Human Services, Public Health Service; 1995.
62. 62 Fischer G, Johnson RE, Eder H, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000; 95:239-244. The first reported prospective study assessing opiate withdrawal signs in neonates born to mothers maintained on buprenorphine.
63. 63 Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001; 63: in press.
64. 64 Robinson SE. Effect of prenatal opioid exposure on cholinergic development. Biomed Sci 2000; 7:253-257.
65. 65 Jernite M, Viville B, Escande B, et al. Buprenorphine and pregnancy. Analysis of 24 cases. Arch Pediatr 1999; 6:1179-1185.
66. 66 Johnson RE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Alcohol Drug Depend 2001; in press.
67. 67 Auriacombe M, Afflelou S, Lavignasse P, et al. Pregnancy, abortion, and delivery in a cohort of heroin-addicted subjects undergoing substitution treatment (methadone and buprenorphine) in aquitaine [abstract]. La Presse Médicale 1999; 28:177.
68. 68 Loustauneau A, Auriacombe M, Fraques P, et al. A report of 18 pregnancies among buprenorphine treated women [abstract]. Drug Alcohol Depend 2000; 60 (Suppl. 1):S132.
69. 69 Annito WJ. Detoxification with buprenorphine of a pregnant heroin addict. Am J Addictions 2000; 9:92-93.
70. 70 O'Connor PG. Treating opioid dependence - new data and new opportunities. N Engl J Med 2000; 343:1332-1334.
71. 71 American Methadone Treatment Association. News Report, 6th ed. 1999. p. 11.
72. 72 Golden NL, Kuhnert BR, Sokol RJ, et al. Neonatal manifestations of maternal phencyclidine exposure. Perinat Med 1987; 15:185-191.
73. 73 Mvula MM, Miller Jr JM, Ragan FA. Relationship of phencyclidine and pregnancy outcome. J Reprod Med 1999; 44:1021-1024.
74. 74 Scher M, Richardson GA, Coble P, et al. The effects of prenatal alcohol and marijuana exposure: disturbances in neonatal sleep cycling and arousal. Pediatr Res 1988; 24:101-105.
75. 75 Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 2000; 22:325-336.
76. 76 Levy M, Spino M. Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy 1993; 13:202-211.
77. 77 Olney JW, Farber NB, Wozníak DF, et al. Environmental agents that have the potential to trigger massive apoptotic neurodegeneration in the developing brain. Environ Health Perspect 2000; 108 (Suppl. 3):383-388.
78. 78 Markovic N, Ness RB, Cefilli D, et al. Substance use measures among women in early pregnancy. Am J Obstet Gynecol 2000; 183:627-632.
79. 79 Zellman GL, Bell RM, Archie C, et al. Physician response to prenatal substance exposure. Maternal Child Health J 1999; 3:29-38. This paper describes results from the first national effort to provide data on what healthcare providers think about and how they respond to prenatal substance abuse. The ramifications on public policy are discussed.
80. 80 Lussky RC. Alcohol use during pregnancy: how health care providers can make a difference. Minn Med 1996; 79:49-51.
81. 81 Matano RA, Wanat SF. Addìction is a treatable disease, not a moral failing. West J Med 2000; 172:63.
82. 82 Diekman ST, Floyd RL, Decoufle P, et al. A survey of obstetrician-gynecologists on their patients' alcohol use during pregnancy. Obstet Gynecol 2000; 95:756-763.
83. 83 Flynn HA, Blow FC, Barry K, Marcus SM. Identification of prevalence and risk factors associated with alcohol consumption among pregnant women [abstract]. Alcohol Exp Clin Res (Suppl.) 1999; 23:111A.
84. 84 Chang G, Goetz MA, Wilkins-Haug L, Berman S. A brief intervention for prenatal alcohol use - an in depth look. J Subst Abuse Treat 2000; 18:365-369.
85. 85 Chang G, Wilkins-Haug L, Berman SA, Goetz MA. Brief intervention for alcohol use in pregnancy: a randomized trial. Addiction 1999; 94:1499-1508. The first randomized controlled trial testing a brief intervention for drinking cessation conducted in pregnant women. Only self-reported alcohol consumption was reported.
86. 86 McMurtrie C, Rosenberg KD, Kerker BD, et al. A unique drug treatment program for pregnant and postpartum substance-using women in New York City: results of a pilot project 1990-1995. Am J Drug Alcohol Abuse 1999; 25:701-713.
87. 87 Hankin J, McCaul ME, Heussner J. Pregnant, alcohol-abusing women. Alcohol Clin Exp Res 2000; 24:1276-1286. An excellent review is presented on the current knowledge regarding the screening and treatment of pregnant alcohol users. Areas for future research are suggested.
88. 88 Jones HE, Haug NA, Stitzer ML, Svikis DS. Improving treatment outcomes for pregnant drug-dependent women using low-magnitude voucher incentives. Addict Behav 2000; 25:263-267.
89. 89 Jones HE, Haug NA, Silverman K, et al. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 2001; 61:297-306.